FDA Accepts Supplement for ILUMYA (Tildrakizumab) by Sun Pharma
The FDA has accepted a supplemental biologics application for ILUMYA (tildrakizumab) from Sun Pharma.
Asset / Drug
Drug and asset intelligence for ILUMYA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.